PREDICTION OF BISPHOSPHONATE-ASSOCIATED
OSTEONECROSIS OF THE JAWS IN BULGARIAN
PATIENTS USING LOGISTIC REGRESSION

Boryana Ilieva$^{1, \S}$, Krasimira Prodanova$^2$, Vassil Sveshtarov$^{1}$
$^1$ Faculty of Dental Medicine
Medical University - Sofia
1, G. Sofiiski Blvd
Sofia - 1431, BULGARIA
$^2$ Technical University of Sofia
8, Kl. Ohridski Blvd
Sofia - 1000 , BULGARIA

Abstract


Abstract. Bisphosphonates are a group of drugs that are widely used in the treatment of osteoclast-mediated diseases related to bone loss. Since 2003 the problem of bisphosphonate-associated osteonecrosis of the jaws (BAONJ) has been raised, and many authors have published the cases they have observed. BAONJ is a multifactorial disease, and the risk factors for the development of the disease can be divided into those related to bisphosphonate therapy, local risk factors, demographic and systemic factors, genetic factors and preventive factors. The aim of the present study is to determine the effect of the duration of bisphosphonate (BF) intake and the period of time from the surgical intervention (TPSI) on the outcome of BAONJ treatment using logistic regression. The obtained models allow to estimate the predicted probability of the occurrence of this complication. The models were based on experimental data from 44 patients who received medical and diagnostic care in the University Hospital “St. Anna" - Sofia, as well as patients treated in an outpatient setting in the Dental Medicine Faculty - Sofia, Bulgaria.

Received: 18 August 2023

AMS Subject Classification: 62F03

Key Words and Phrases: bisphosphonate-associated osteonecrosis of the jaws, logistic regression

Download paper from here.

How to cite this paper?
DOI: 10.12732/ijam.v36i6.6
Source: International Journal of Applied Mathematics
ISSN printed version: 1311-1728
ISSN on-line version: 1314-8060
Year: 2023
Volume: 36
Issue: 6
Back to Contents

References

  1. [1] M.M. Sobh, M. Abdalbary, S. Elnagar, E. Nagy, N. Elshabrawy, M. Abdelsalam, K. Asadipooya, A. El-Husseini, Secondary Osteoporosis and Metabolic Bone Diseases, J. Clin. Med., 11, No 9 (2022), 2382-2391; doi:10.3390/jcm11092382.
  2. [2] M. Gupta, N. Gupta, Bisphosphonate Related Jaw Osteonecrosis, StatPearls Publishing, Treasure Island (Florida) (2023); https://www.ncbi.nlm.nih.gov/books/NBK534771/.
  3. [3] M. Nashi, K. Kishimoto, M. Kobayashi et al., Incidence of antiresorptive agent-related osteonecrosis of the jaw: A multicenter retrospective epidemiological study in Hyogo Prefecture, Japan. J. Dent. Sci., 18, No 3 (2023), 1156-1163.
  4. [4] Badros et al., Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors, J. Clin. Oncol., 24, No 6 (2006), 945-952; doi:10.1200/JCO.2005.04.2465.
  5. [5] Bamias, Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors, J. Clin. Oncol., 23, No 34 (2005), 8580-8587; doi:10.1200/JCO.2005.02.8670.
  6. [6] J.J. Body, Breast cancer: bisphosphonate therapy for metastatic bone disease, Clin. Cancer Res., 12 (2006), 6258s-6263s; doi:10.1158/1078-0432.CCR-06-0840.
  7. [7] M. Jovanovic, G. Guterman-Ram, J.C. Marini, Osteogenesis imperfecta: Mechanisms and signaling pathways connecting classical and rare OI types, Endocrine Reviews, 43, No 1 (2022), 61-90; doi:10.1210/endrev/bnab017.
  8. [8] R.E. Marx, Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic, J. of Oral and Maxillofacial Surgery, 61, No 9 (2003), 1115-1157; doi:10.1016/s0278-2391(03)00720-1.
  9. [9] S. Ruggiero et al., American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update, J. of Oral and Maxillofacial Surgery, 72, No 10 (2014), 1938-56; doi:10.1016/j.joms.2014.04.031.
  10. [10] S.L. Ruggiero, Bisphosphonate-related osteonecrosis of the jaw (BRONJ): initial discovery and subsequent development, J. of Oral and Maxillofacial Surgery, 67, No 5 (2009), 13-18.
  11. [11] T. Shibahara, T. Morikawa, K. Yago et al., National survey on bisphosphonate-related osteonecrosis of the jaws in Japan, J. of Oral and Maxillofacial Surgery, 76, No 10 (2018), 2105-2112.
  12. [12] T. Shintani, Y. Hayashido, H. Mukasa Het al., Comparison of the prognosis of bisphosphonate-related osteonecrosis of the jaw caused by oral and in travenous bisphosphonates, Int. J. Oral Maxillofac. Surg., 44, No 7 (2015), 840-844.
  13. [13] J.P. Bodem, C. Schaal, S. Kargus et al., Surgical management of bisphosphonate-related osteonecrosis of the jaw stages II and III, Oral Surg. Oral Med. Oral Pathol. Oral Radiol., 121, No 4 (2016), 367-372.
  14. [14] N.R. Choi, J.H. Lee, J.Y. Park, D.S. Hwang, Surgical treatment of medication-related osteonecrosis of the jaw: A retrospective study, Int. J. Environ. Res. Public Health, 17, No 23 (2020), 8801.
  15. [15] T. Yasui, H. Tanaka et al., Treatment outcomes and time to healing of medication-related osteonecrosis of the jaw based on image findings Dentomaxillofac Radiol., 52, No 5 (2023), 20220352; doi:10.1259/dmfr.20220352.
  16. [16] StatSoft, Inc., STATISTICA Manual (Data Analysis Software System), Version 11.0, US (2018).
  17. [17] J.D. Jobson, Multivariate Data Analysis, Springer Ver., Berlin (1991).
  18. [18] Y. Uzunova, K. Prodanova, Comparison of binary regression models for the outcome of pediatric liver transplantation, International Journal of Applied Mathematics, 35, No 4 (2022), 495-501; doi:10.12732/ijam.v35i4.8.
  19. [19] M. Negreva, Thromboembolic stroke predictors in paroxymal atrial fibrillation Cox modeling based on studied hemostasis indicators, International Journal of Applied Mathematics, 35, No 6 (2022), 875-885; doi:10.12732/ijam.v35i6.6.
  20. [20] U. Tonggumnead, A comparative study on the efficiency of test statistics in testing the differences between two dependent datasets, International Journal of Applied Mathematics, 34, No 1 (2021), 43-74; doi:10.12732/ijam.v34i1.2.